RIN Institute Announces First-In-Human Dose of RN-1101, A Monoclonal Antibody For Colorectal Cancer Treatment In Phase I Clinical Trial

RIN Institute (Tokyo, Japan; President: Kentaro Yoshimatsu), a clinical-stage biotechnology company focused on the treatment of colorectal cancer (CRC) through monoclonal antibody (mAb) therapeutics, has entered a Phase I clinical trial for its lead candidate, RN-1101. This first-in-human study was initiated at the National Cancer Center Japan (NCC) Hospital in Chiba, where RIN Institute originated. A second facility at NCC is expected to join the trial in the near future.

RN-1101 is a monoclonal antibody targeting the membrane protein Transmembrane Protein 180 (TMEM180), which is highly expressed on colon cancer cells. The study consists of two phases: a dose-escalation phase assessing safety and pharmacokinetics in solid tumor patients, and a cohort expansion phase assessing safety and efficacy in patients with CRC. The clinical trial is supported by the national CiCLE grant.

RN-1101 exerts its anti-cancer effects through antibody-dependent cellular cytotoxicity (ADCC) and has demonstrated therapeutic potential regardless of the presence or absence of KRAS gene mutations.

Colorectal cancer remains a leading cause of cancer-related death, underscoring the need for novel target antigens for mAb development. Fast Track Initiative (FTI) continues to support RIN Institute as an existing shareholder, and remains committed to advancing the company’s research and development of RN-1101 and TMEM180-based therapies for CRC.

Visit https://rinmab.co.jp/archives/1343 to view the original announcement.  

  About RIN Institute: RIN Institute was established in 2016 in Tokyo, Japan as a venture originating from Japan’s National Cancer Center (NCC). As head of RIN Institute and the new drug development field at the NCC Advanced Medical Development Center, Yasuhiro Matsumura, MD, PhD has been working to develop new antibody drugs for therapeutics and diagnostics in cancer treatment by utilizing its own patented monoclonal antibodies. RIN Institute continues to strive to accelerate its development of new innovative antibodies for anti-cancer drugs and diagnostic drugs with the support of NCC. The company name "RIN " is the abbreviation for Robust Immuno-diagnosis and therapy against malignant Neoplasm. For further inquiries, please email us at inforinmab.co.jp or visit us on the web at https://rinmab.co.jp/   About NCCJ: Established by the Ministry of Health, Labor, and Welfare of Japan (MHLW) in 1962, the National Cancer Center (NCC) leads Japan’s cancer treatment, prevention, control programs, research, and education. President Dr. Hitoshi Nakagama leads the workforce of 3900+ as they participate and lead expert bodies appointed by the MHLW in the fight against cancer. Expertise is shared with the medical profession globally, with a focus on Asia. In 2010, it was designated as an incorporated administrative agency (autonomous public service body), followed by a national R&D agency in 2015, respectively remaining under the auspices of the MHLW. Please visit us at https://www.ncc.go.jp/en/ for more details. For media inquiries, email ncc-adminn@cc.go.jp   About Fast Track Initiative: Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to their exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com  for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/. For press inquiries or investor inquiries, please email:  message.us@fasttrackinitiative.com   Sources:

1. Shiraishi, T., Ikeda, K., Tsukada, Y. et al.High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer 21, 302 (2021). https://doi.org/10.1186/s12885-021-08046-6